Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany based Novosom has received patents for both the US and Europe for its drug Delivery technology Smarticles.
Subscribe to our email newsletter
Smarticles are fully charge reversible liposomes for the in vivo drug delivery of nucleotides like siRNA or antisense to targeted cells.
Steffen Panzner, founder and chief scientific officer of Novosom, said: “The broad grant of this family of patents in key jurisdictions reflects the originality of our approach in the field of oligonucleotide delivery. Both offices have accepted wide claim language which secures comprehensive protection of the amphoteric liposome concept irrespective of any chemical representation for Novosom and its licensees.”